Aims and objectives
Loco-regional therapy is the most commonly used treatment for HCC.
This constitutes percutaneous ablative techniques and trans- arterial chemoembolizaion (TACE) .
The percutaneous ablation can be achieved by a number of ways depending on the technique employed for ablating the tumor.
This could be either radiofrequency ablation (RFA),
microwave/laser ablation and chemical ablation with either ethanol (PEI) or acetic acid ablation (PAI) .TACE involves delivery of mixture of chemotherapeutic drugs with iodised oil (lipiodol) through the hepatic artery feeding the malignant liver tumor and subsequently...
Methods and materials
Ethic clearance from the Institute Ethics committee was obtained and a written informed consent was taken.
In this prospective diagnostic study,
consecutive patients of unresectable HCC who had been subjected to any form of locoregional therapy(RFA/PAI/TACE) were enrolled.
The inclusion criteria was the following- HCC patients treated with locoregional therapy in the last one week having focal liver mass < 10 cm,
mass well seen on US ,
and patients willing for timely follow up .
Patients more than 65 years,
ones with diffuse liver...
Results
Forty nine patients with 54 HCC were enrolled.
They had been subjected to various types of locoregional therapies - TACE (32) ,
RFA (6) ,
PAI(9) and TACE followed by PAI (2 ).The mean age was 52.7 years with a male/female ratio of 6:1.
The mean mass size was 4.6 cm +2.33 (range 1-10 cm).
CEUS was done at 4 weeks following treatment..
Enhancement of the viable tissue was seen in 37/54 (68.5%) masses and various patterns of enhancement were noted .
The commonest pattern...
Conclusion
CEUS has a high diagnostic accuracy compared with MPCT in detection of residual disease in patients of HCC treated with locoregional therapies.
Personal information
Dr.
Shashi Paul
Presenting Author
Scientist
Department of Radiodiagnosis
All India Institute of Medical Sciences
New Delhi (INDIA)
Area of Interest-Liver Cancer
References
Livraghi T,
Goldberg SN,
Lazzaroni S et al.
Hepatocellular carcinoma:Radiofrequency ablation of medium and large lesions.
Radiology 2000,214:761-768
Xu HX.
Contrast-enhanced ultrasound: The evolving applications.World J Radiol.
2009;1:15-24.
Xia Yu,
Kudo M,
Minami Y,
Hatanaka K,
Ueshima K,
Chung H,
Hagiwara S et al.
Response evaluation of Transarterial chemoembolization in Hepatocellular carcinomas: The usefulness of sonazoid-enhanced harmonic sonography.Oncology 2008;75:99-105
Nicolau C,
Catala V,
Vilana R,
Gilabert R,
Bianchi L,
Sole M,
et al.
Evaluation of hepatocellular carcinoma using SonoVue,
a second generation ultrasound contrast agent:correlation...